Gentel Biosciences

PATH™ Product Promises Superior Technology For Users, Strong ROI for Investors

Currently, protein biochip use is largely limited to assay development in research laboratories. “PATH technology will help scientists move beyond basic research to drug discovery and development, and diagnostics,” Vodenlich said.

Early response from the scientific community has GenTel readying for orders at and following the product’s international debut in Boston, “Our sales-to-date have been encouraging. We’re eager to make the product available to an international target audience,” he said.

Biochip consumers include academic and industrial research laboratories that are using the technology to diagnose and manage disease, and for new drug development. The total biochip market is predicted to exceed $1 billion by the end of 2005, with a compound annual growth rate of greater than 70 percent, according to a 2003 report published by BioInsights.

The PATH technology was developed by Clinical MicroArrays, Inc. of Natick, Mass., and is licensed to GenTel BioSurfaces. It is the first of several products that the firm plans to release within the coming months, and is the company’s second product launch.

More information about GenTel BioSurfaces, Inc. can be obtained at www.gentelbio.com or by contacting:
- Alex D. Vodenlich, president and CEO at 608-217-5587; This e-mail address is being protected from spambots. You need JavaScript enabled to view it
or
- Sarah Botham, Front Porch Communications at 608-924-2625, This e-mail address is being protected from spambots. You need JavaScript enabled to view it .